Aptivus

Generic name: Tipranavir

Drug class: Non-peptidic protease inhibitor

Dosage form: Oral capsule, oral solution

Root of administration: Oral

Dose: Adults: 500 mg twice daily with 200 mg ritonavir; Children ≥2 years: 14 mg/kg twice daily with 6 mg/kg ritonavir (maximum 500 mg/dose)

Mechanism of action: Tipranavir inhibits HIV-1 protease, preventing maturation of viral particles and inhibiting viral replication. It is effective against HIV strains resistant to other protease inhibitors

Drug usage cases:

• Treatment of HIV-1 infection in combination with ritonavir for patients with strains resistant to multiple protease inhibitors

Drug contra indications:

• Moderate or severe hepatic impairment (Child-Pugh B or C)
• Concomitant use with potent CYP3A inducers or substrates (e.g., rifampin, St. John’s wort)
• Concomitant use with colchicine in patients with renal or hepatic impairment

Side effects:

• Common: Diarrhea, nausea, vomiting, abdominal pain, fatigue, headache
• Serious: Hepatotoxicity, intracranial hemorrhage, rash (including severe forms), hyperglycemia, hyperlipidemia

Warnings:

• Monitor liver function tests regularly; discontinue if signs of hepatic decompensation occur
• Risk of intracranial hemorrhage; exercise caution in patients with bleeding disorders
• Potential for significant drug interactions; consult healthcare provider before starting new medications

Use during pregnancy or breastfeeding: Limited data available; consult healthcare provider to assess potential risks and benefits